Karyopharm: Millennium reports 0.2% ownership stake
Voting and disposition authority is reported as shared, while each reporting person's sole power is listed as zero.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Karyopharm Therapeutics Inc.'s amended ownership disclosure lists Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each as beneficially owning 42,888 shares, or 0.2%, reported as of September 30, 2026. Each reports shared voting and dispositive power over 42,888 shares and zero sole voting or dispositive power. The disclosure states that securities potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander are held by entities, and that the disclosure is not itself an admission of beneficial ownership.
Key Figures
Key Terms
beneficially owned regulatory
Joint Filing Agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.